ArticlePharmacoEconomics2020

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.

Sang Kyu Cho et al.PubMed ↗Publisher ↗

No numbers read from the abstract.